Oryzon and CMTRF Join Forces to Develop HDAC6 Inhibitors for CMT
The CMT Research Foundation (CMTRF) is teaming up with Oryzon Genomics to conduct preclinical testing of treatments that Oryzon is developing for Charcot-Marie-Tooth disease (CMT). “We are excited to collaborate with Oryzon on this important project,” Cleary Simpson, CEO of the foundation, said in a press…